The ASCO Post™ is published by Harborside Press, LLC under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Harborside Press, HSP News Service, LLC, and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions. |
|
|
As reported in The Lancet Oncology by Nancy Y. Lee, MD, and colleagues, the phase III JAVELIN Head and Neck 100 trial showed no improvement in progression-free survival with the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy in patients with previously untreated locally advanced squamous cell carcinoma of the head and neck.
As reported in the Journal of Clinical Oncology by Sibylle Loibl, MD, PhD, and colleagues, the phase III PENELOPE-B trial has shown that palbociclib plus endocrine therapy did not improve invasive disease–free survival vs placebo plus endocrine therapy in patients with residual invasive hormone receptor (HR)-positive, HER2-negative breast cancer following neoadjuvant chemotherapy.
As reported in the Journal of Clinical Oncology by Carlos Rodriguez-Galindo, MD, and colleagues, the Children’s Oncology Group ARAR0332 Protocol has identified outcomes associated with different treatment strategies according to disease stage in patients with pediatric adrenocortical carcinoma.
